Loading investment pitches...
Equity Research Database
Institutional Investment Pitches
Explore thousands of hedge fund pitches, high-conviction equity research memos, and portfolio manager commentary extracted from quarterly letters.
Explore thousands of hedge fund pitches, high-conviction equity research memos, and portfolio manager commentary extracted from quarterly letters.
The Fund holds an opportunistic position in DiaMedica Therapeutics (DMAC), a clinical-stage biotechnology company that has developed DM199, a recombinant (synthetic) form of the naturally occurring tissue kallikrein-1 (KLK1) protein — a critical molecular trigger for blood-vessel dilation. Stroke Indication ($10...
— Yaron Naymark
Full equity research memos, financial breakdowns, and hedge fund thesis write-ups are reserved for BSD Research ($50/mo) and Pro subscribers.
Already a Research or Pro subscriber? Sign In
Other investors who've written on DIAMEDICA THERAPEUTICS INC
More institutional theses from 1 Main Capital
I discussed KKR in the Q1’26 letter, and not much has changed in my thinking. The business continues...
This year the Fund initiated a position in WILD, a kids’ content company that recently completed the sale of its Peanuts (Snoopy) stake to Sony for C$630 million, which took the company from 5x net levered to net cash. Prior to the...
BFIT has continued to execute since we reinitiated the investment in 2024. In its most...